Delcath SystemsDCTH
DCTH
About: Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Employees: 76
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
171% more call options, than puts
Call options by funds: $1.95M | Put options by funds: $717K
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
58% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 26
12% more capital invested
Capital invested by funds: $165M [Q4 2024] → $184M (+$19.4M) [Q1 2025]
9% more funds holding
Funds holding: 90 [Q4 2024] → 98 (+8) [Q1 2025]
2.38% more ownership
Funds ownership: 42.8% [Q4 2024] → 45.18% (+2.38%) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$29
89%
upside
Avg. target
$29
89%
upside
High target
$29
89%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth | 89%upside $29 | Buy Maintained | 23 May 2025 |
Financial journalist opinion
Based on 6 articles about DCTH published over the past 30 days
Neutral
Seeking Alpha
2 days ago
Delcath Systems: Growing Fast, But Business Model Is Fragile
Delcath's HEPZATO shows rapid sales growth and high pricing, but its efficacy is only moderately better than alternatives and not curative. The addressable market is small, treatment is complex, and future competition from Replimune or Ideaya could threaten long-term prospects and valuation multiples. Financials are solid with no debt, recent profitability, and reasonable stock-based compensation; forward P/S ratio is attractive versus peers.
Positive
Zacks Investment Research
1 week ago
Delcath Systems, Inc. (DCTH) Is Up 0.62% in One Week: What You Should Know
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts Predict a 48.69% Upside in Delcath Systems (DCTH): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 48.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
2 weeks ago
Here's Why Momentum in Delcath Systems (DCTH) Should Keep going
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
Business Wire
3 weeks ago
Delcath Systems Issues Full Year 2025 Guidance
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement (NDRA) to expand patient access. 2025 Full Year Financial Guidance The Company's financial outlook for fiscal year 2025 is as follows: Total CHEMOSAT and HEPZATO KIT revenu.
Positive
Seeking Alpha
3 weeks ago
Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution
Delcath's commercial execution post-HEPZATO launch has driven impressive revenue growth, positive cash flow, and a shift from speculative to established biotech. Q1 earnings beat expectations with 530% revenue growth, positive EBITDA, and net income, validating the company's scalability and operational progress. Growth drivers include expanding U.S. treatment centers, pipeline development for new indications, and commercial initiatives, though risks remain around execution and clinical milestones.
Neutral
Business Wire
1 month ago
Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025 at The Depot Renaissance Hotel in Minneapolis, MN. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of.
Neutral
Business Wire
1 month ago
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to eleven individuals whose employment commenced in March and April of 2025. The grants resulted in the right to purchase 111,000 shares of the Company's.
Neutral
Seeking Alpha
1 month ago
Delcath Systems, Inc. (DCTH) Q1 2025 Earnings Call Transcript
Delcath Systems, Inc. (NASDAQ:DCTH ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel – CEO Sandra Pennell - SVP, Finance Vojislav Vukovic - Chief Medical Officer Kevin Muir - General Manager, Interventional Oncology Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Swayampakula Ramakanth - H.C. Wainwright Marie Thibault - BTIG Sudan Loganathan - Stephens Bill Maughan - Clear Street Yale Jen - Laidlaw & Company Operator Good day and welcome to the Delcath Systems' First Quarter 2025 Earnings Call.
Negative
Zacks Investment Research
1 month ago
Delcath Systems, Inc. (DCTH) Misses Q1 Earnings Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.43 per share a year ago.
Charts implemented using Lightweight Charts™